Novavax appoints Rick Crowley as Executive Vice President, Chief Operations Officer.

pharmafile | December 22, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has announced the appointment of Rick Crowley to the newly created position of Executive Vice President, Chief Operations Officer.

In this role, Crowley will have leadership responsibility for all operations, including Quality, Manufacturing, Supply Chain and Regulatory Affairs. He takes over manufacturing from Ben Machielse, who will continue with the company as an Executive Advisor to the Chief Executive Officer, supporting the development of the COVID-19 vaccine.

Before joining Novavax, Crowley was Executive Vice President of Technical Operations for TerSera Pharmaceuticals. He served as Senior Vice President, Operations and Quality Assurance for Crealta Pharmaceuticals between 2014 and 2016, where he led all aspects of the supply chain function, managed suppliers and testing, and held responsibility for the management of Regulatory Affairs. Prior to these roles, Crowley was Co-President and Chief Operating Officer at Savient Pharmaceuticals, and earlier in his career held position of increasing responsibility at ImClone Systems, Incorporated and BASF Bioresearch Corp.

Stanley C. Erck, Novavax President and Chief Executive Officer, said: “Rick’s wealth of biopharmaceutical experience and record of on-time FDA approvals comes at the perfect time to help ensure that Novavax delivers on our global manufacturing mission and supply commitments.

“We welcome his leadership as we work to advance not only our COVID-19 candidate, but also influenza and RSV vaccines.”

Related Content

No items found

Latest content